NCT04009109 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

October 1, 2025

Study Completion Date

July 1, 2026

Conditions

Myeloma, Multiple

Interventions

DRUG

Lenalidomide

Induction and Maintenance

DRUG

Ixazomib

Induction and Only Maintenance Arm B

DRUG

Daratumumab Injection

Induction and Only Maintenance Arm B

DRUG

Dexamethasone

Induction and Only Maintenance Arm B

Trial Locations (7)

SUNY Upstate Medical Center, Syracuse

University of North Carolina, Chapel Hill

Gibbs Cancer Center & Research Institute/Spartanburg Regional Healthcare, Spartanburg

University of Nebraska Medical Center, Omaha

Northern Light Eastern Maine Medical Center, Bangor

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston